Skip to main
ACTU
ACTU logo

ACTU Stock Forecast & Price Target

ACTU Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Actuate Therapeutics Inc's development of elraglusib has shown significant clinical promise, as evidenced by improved median overall survival and one-year survival rates in patients with metastatic pancreatic adenocarcinoma, compared to existing treatments. The company has bolstered its financial position through a recent funding round, allowing it to explore various regulatory pathways and support upcoming clinical trials that may underline the efficacy of elraglusib. With substantial resources now available, Actuate is well-positioned to advance its research and operational capabilities, which could lead to positive regulatory outcomes in the near future.

Bears say

Actuate Therapeutics Inc is facing financial challenges characterized by a significant cash burn rate that raises concerns about its ability to fund ongoing development programs for elraglusib and other pipeline candidates. Additionally, the company has reported disappointing clinical trial results, which may hinder regulatory approval and market entry, thereby limiting potential revenue generation. Furthermore, the competitive landscape in cancer therapeutics poses a risk, as established players may outpace Actuate Therapeutics in delivering effective treatment solutions, impacting investor confidence and stock performance.

ACTU has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Actuate Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Actuate Therapeutics Inc (ACTU) Forecast

Analysts have given ACTU a Strong Buy based on their latest research and market trends.

According to 2 analysts, ACTU has a Strong Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Actuate Therapeutics Inc (ACTU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.